Eli Lilly and Company (NYSE:LLY) Shares Sold by Regent Peak Wealth Advisors LLC

Regent Peak Wealth Advisors LLC lessened its stake in Eli Lilly and Company (NYSE:LLYFree Report) by 1.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 2,640 shares of the company’s stock after selling 31 shares during the period. Regent Peak Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,539,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. JGP Wealth Management LLC raised its position in shares of Eli Lilly and Company by 0.9% in the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after buying an additional 16 shares during the period. Cassia Capital Partners LLC raised its position in shares of Eli Lilly and Company by 1.8% in the 3rd quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock worth $511,000 after buying an additional 17 shares during the period. Walkner Condon Financial Advisors LLC raised its position in Eli Lilly and Company by 2.8% in the third quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock valued at $334,000 after purchasing an additional 17 shares during the period. Patton Albertson Miller Group LLC raised its position in Eli Lilly and Company by 2.8% in the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock valued at $335,000 after purchasing an additional 17 shares during the period. Finally, Valley Wealth Managers Inc. raised its position in Eli Lilly and Company by 1.3% in the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after purchasing an additional 17 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on LLY shares. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research report on Wednesday, February 21st. Morgan Stanley lifted their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Barclays lifted their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, Citigroup lifted their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $700.00.

Check Out Our Latest Research Report on LLY

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 14,388 shares of the business’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $630.28, for a total transaction of $9,068,468.64. Following the sale, the insider now owns 99,754,422 shares of the company’s stock, valued at $62,873,217,098.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 195,055 shares of company stock valued at $125,254,657 over the last quarter. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded up $3.41 during midday trading on Tuesday, hitting $763.96. 2,552,667 shares of the company’s stock were exchanged, compared to its average volume of 3,221,156. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The stock’s 50 day moving average price is $739.63 and its 200-day moving average price is $641.00. The firm has a market cap of $725.88 billion, a P/E ratio of 131.72, a PEG ratio of 1.71 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $342.30 and a twelve month high of $800.78.

Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the previous year, the firm posted $2.09 earnings per share. The business’s revenue was up 28.1% on a year-over-year basis. Equities research analysts anticipate that Eli Lilly and Company will post 12.42 EPS for the current year.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.